Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116646 | 0.85 | TXNRD1 (0.40) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL10305220 | 0.83 | TXNRD1 (0.39) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL8125480 | 0.83 | TXNRD1 (0.39) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL21839054 | 0.82 | NPC1 (0.46) | NPC1RAB9AERN1GPR35MAPT | |
| SCHEMBL21198065 | 0.82 | NPC1 (0.46) | NPC1RAB9AERN1GPR35MAPT | |
| SCHEMBL3029367 | 0.82 | MAPT (0.39) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL13222350 | 0.82 | TXNRD1 (0.38) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL3027768 | 0.82 | MAPT (0.39) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL4523570 | 0.80 | TXNRD1 (0.36) | TXNRD1TXNRD3TXNRD2NPC1RAB9A | |
| SCHEMBL13222372 | 0.80 | MAPT (0.44) | TXNRD1TXNRD3TXNRD2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | claimed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | claimed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | claimed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | claimed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | claimed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | disclosed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | disclosed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | disclosed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | disclosed |
| WO-1999002161-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | FORSSMANN WOLF GEORG (DE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | PDE5A, PDE7A, PDE12 | TXNRD1 2016/4885TXNRD3 2049/4885TXNRD2 2099/4885 |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | PDE12, PDE5A, QDPR | TXNRD1 2004/4885TXNRD3 2157/4885TXNRD2 2070/4885 |
| US-20020025969-A1 | Genign prostatic hyperolasia | PDE5A, PDE3A, PDE2A | TXNRD1 961/4885TXNRD3 730/4885TXNRD2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.